Who should not take HRT? Contraindications explained

Systemic hormone therapy, meaning estrogen pills, patches, gels and sprays, is generally not used if you have unexplained vaginal bleeding, current or past breast cancer or another estrogen-sensitive cancer, a past blood clot, stroke or heart attack, an inherited clotting disorder, or liver disease. A longer list of conditions calls for caution or a different route rather than a flat no. And some common worries, such as a mother’s breast cancer, are not contraindications at all.

The quick guide

Category	Conditions	What it usually means
Contraindications to systemic therapy	Unexplained vaginal bleeding; breast cancer now or in the past; other estrogen-dependent cancer; current or past deep vein clot or lung clot; past stroke or heart attack; inherited clotting disorders such as protein C, protein S or antithrombin deficiency; liver disease; pregnancy	Systemic hormone therapy is generally not used; nonhormonal options instead
Caution, weigh benefits and risks	High triglycerides; past cholestatic jaundice; migraine, epilepsy, asthma, diabetes, lupus or porphyria; hereditary angioedema; low parathyroid function; endometriosis after hysterectomy	Individual decision, often with monitoring or a different route
Route matters	Obesity, older age, kidney disease, other clot risk factors	A patch or gel is generally preferred over a pill
Timing	Starting after 60 or more than 10 years past menopause	Less favorable balance; careful assessment
Not contraindications	Family history of breast cancer; prior benign breast biopsy; type 2 diabetes in an otherwise healthy woman; treated hypothyroidism	Hormone therapy can be considered

The firm contraindications, and why

The Menopause Society’s 2022 position statement lists unexplained vaginal bleeding, liver disease, prior estrogen-sensitive cancer including breast cancer, prior coronary heart disease, stroke, heart attack or venous clot, and a personal history or inherited high risk of clots. The estradiol gel label revised in February 2026 gives nearly the same list and adds known hypersensitivity to the product. ACOG’s patient guidance adds pregnancy.

• Unexplained bleeding comes first because it has to be investigated, including for endometrial cancer, before any hormone is started. Once the cause is known and treated, therapy may be possible.
• Breast and other estrogen-dependent cancers can be stimulated by estrogen. The numbers for women without cancer are in hormone therapy and breast cancer risk.
• Clots, stroke and heart attack. In the WHI, estrogen alone and estrogen plus progestin each raised the risk of venous clots and stroke across the trial population. A woman who has already had one of these events starts from a much higher baseline.
• Inherited clotting disorders. Labels name protein C, protein S and antithrombin deficiency. ACOG notes that women with factor V Leiden or the prothrombin G20210A mutation are also especially at risk.
• Liver disease. The label notes estrogens may be poorly metabolized when the liver is impaired.

The progestogen has its own list. Micronized progesterone capsules carry the same contraindications for bleeding, breast cancer, clots and liver disease, plus a peanut allergy, because the capsules contain peanut oil.

Conditions that call for caution

The revised estradiol label asks clinicians to weigh benefits and risks, or monitor closely, in several situations:

• High triglycerides, which estrogen can raise further, occasionally to the point of pancreatitis.
• A history of cholestatic jaundice with past estrogen use or pregnancy.
• Migraine, epilepsy, asthma, diabetes, lupus, porphyria and liver hemangiomas, which estrogen may worsen. If migraine is your concern, see our guide to perimenopause with migraine.
• Hereditary angioedema, which estrogen can worsen.
• Hypoparathyroidism, because of a risk of low calcium.
• Endometriosis after hysterectomy, where a progestogen may be added.
• Heart or kidney conditions that predispose to fluid retention.
• Thyroid replacement. Women taking thyroid hormone may need a higher dose, so levels should be monitored.

Labels also advise stopping estrogen, if feasible, 4 to 6 weeks before surgery that carries a high clot risk or during long immobilization. On blood pressure, the label notes rare individual rises in case reports but no general effect in a large randomized trial.

When the route is the answer

Clot risk is where the form of estrogen matters most. ACOG’s committee opinion on route of administration explains that clot risk rises with age and with risk factors such as cardiovascular disease, obesity, fracture, kidney disease and inherited or acquired clotting disorders, and asks prescribers to consider the clot-sparing properties of transdermal estrogen.

The largest study supports that. In UK data on 80,396 women with a clot matched to 391,494 controls, oral hormone therapy raised the odds of a clot 1.58-fold overall and 2.10-fold for conjugated estrogen with medroxyprogesterone acetate, while transdermal estrogen showed no increase (0.93). The Menopause Society notes that no randomized trial has compared routes directly. For many women with extra clot risk but no prior clot, an estrogen patch or gel is the practical answer.

Age and timing

The Menopause Society’s framework is anchored on age: the benefit-risk balance is favorable for healthy women under 60 or within 10 years of menopause, and less favorable for women who start later, because the absolute risks of heart disease, stroke, clots and dementia are higher. In the WHI, starting after 70 carried the highest risk. Continuing therapy that began earlier is a different question; there is no routine stopping age, as explained in how long you can take HRT.

New hot flashes that appear many years after menopause deserve a workup before treatment. The Menopause Society lists sleep apnea, an overactive thyroid, some cancers, infections and certain medications as possible causes.

What is not a contraindication

The Menopause Society reports that, in observational studies, hormone therapy does not further raise the relative risk of breast cancer in women with a family history, women with a prior benign breast biopsy, or BRCA carriers who had their ovaries removed young. It also states that hormone therapy is not contraindicated in otherwise healthy women with type 2 diabetes. Treated hypothyroidism needs monitoring, not avoidance.

If hormone therapy is not for you

Effective alternatives exist. Our guide to nonhormonal treatments for hot flashes compares the prescription options. For vaginal dryness, low-dose vaginal estrogen is assessed separately from systemic therapy and is sometimes still possible.

Questions to ask

• Is anything in my history a firm contraindication, or a reason for caution?
• Would a patch or gel lower my risk compared with a pill?
• Do I need any tests first, such as a lipid panel or an evaluation of bleeding?
• If systemic therapy is ruled out, what are my best alternatives?

Our OB-GYN directory lists clinicians by city if you want a second opinion.